Factors influencing clinically meaningful recanalization after IV-rtPA in acute ischemic stroke

AJNR Am J Neuroradiol. 2013 Jan;34(1):146-52. doi: 10.3174/ajnr.A3169. Epub 2012 Jun 14.

Abstract

Background and purpose: Recanalization may not result in better clinical outcomes after ischemic stroke. We determined the incidence and significant predictors of CMR, defined as CT angiographic recanalization and a good clinical outcome, after IV-rtPA in acute ischemic stroke. A CMR score was devised and tested.

Materials and methods: One hundred twenty-six consecutive patients with anterior circulation ischemic stroke receiving IV-rtPA were retrospectively reviewed. Imaging included a baseline NCCT and CTA. Recanalization was assessed on a 24-hour CTA. Clinical outcome was determined by the 90-day mRS. CMR was defined as CTA recanalization and a good clinical outcome (mRS ≤2). Logistic regression analysis determined predictors of CMR. The predictive ability of a CMR score was tested with AIC.

Results: CMR occurred in 29% (36/126). Patients with CMR had fewer neurologic deficits (P = .001) and higher ASPECTS (P = .041) at baseline than those without CMR. Baseline NIHSS score did not predict proximal occlusion (OR 0.959; 95% CI [0.907-1.014]; P = .141). Multivariate analysis showed admission NIHSS score (P = .001) and the site of vessel occlusion (P = .022) to be significant CMR predictors. CMR was significantly less likely in patients with proximal occlusions (ICA, P = .005; proximal M1, P = .021). A CMR score better predicted CMR than either NIHSS or vessel occlusion site alone (P < .0001).

Conclusions: Milder baseline stroke deficit and distal vessel occlusion are significant predictors of CMR. A combination of these parameters better predicts CMR than either parameter alone.

MeSH terms

  • Aged
  • Brain Ischemia / diagnostic imaging*
  • Brain Ischemia / epidemiology
  • Brain Ischemia / prevention & control*
  • Cerebral Angiography / statistics & numerical data*
  • Comorbidity
  • Fibrinolytic Agents / administration & dosage
  • Humans
  • Ontario / epidemiology
  • Outcome Assessment, Health Care / methods
  • Outcome Assessment, Health Care / statistics & numerical data
  • Prevalence
  • Prognosis
  • Recombinant Proteins / administration & dosage
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Factors
  • Sensitivity and Specificity
  • Stroke / diagnostic imaging*
  • Stroke / epidemiology
  • Stroke / prevention & control*
  • Tissue Plasminogen Activator / administration & dosage*
  • Tissue Plasminogen Activator / genetics
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator